Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kymera Therapeutics, Inc.

45.14
-1.0400-2.25%
Post-market: 45.140.00000.00%16:23 EDT
Volume:620.60K
Turnover:28.58M
Market Cap:3.17B
PE:-14.50
High:47.11
Open:46.52
Low:44.92
Close:46.18
Loading ...

Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue Cdk2 Degraders

THOMSON REUTERS
·
25 Jun

Gilead Sciences Inc - Kymera Eligible to Receive up to $750 Mln in Payments

THOMSON REUTERS
·
25 Jun

Gilead Sciences Inc - Deal Expected to Reduce Gilead's 2025 EPS by $0.02-$0.03

THOMSON REUTERS
·
25 Jun

Director Elena Ridloff Reports Disposal of Kymera Therapeutics Inc. Common Shares

Reuters
·
12 Jun

Kymera Therapeutics (KYMR) Gets a Buy from Stifel Nicolaus

TIPRANKS
·
09 Jun

Wall Street Shows Love for Kymera Stock After Biotech's Promising Drug Trial -- Barrons.com

Dow Jones
·
06 Jun

Director Jeffrey W. Albers Reports Disposal of Common Shares of Kymera Therapeutics Inc

Reuters
·
04 Jun

BUZZ-U.S. STOCKS ON THE MOVE-Guardant Health, Hewlett Packard Enterprise, Venture Global

Reuters
·
04 Jun

UBS Keeps Their Buy Rating on Kymera Therapeutics (KYMR)

TIPRANKS
·
04 Jun

Kymera STAT6 Degrader Phase 1 Data a 'Key De-Risking Event,' Morgan Stanley Says

MT Newswires Live
·
03 Jun

BUZZ-Brokerages turn bullish on Kymera after positive early trial data

Reuters
·
03 Jun

Kymera Therapeutics Is Maintained at Overweight by JP Morgan

Dow Jones
·
03 Jun

Kymera Therapeutics Inc : Morgan Stanley Raises to Overweight From Equal-Weight

THOMSON REUTERS
·
03 Jun

Kymera Therapeutics Inc : Guggenheim Raises Target Price to $60 From $52

THOMSON REUTERS
·
03 Jun

Kymera Therapeutics Inc : Citigroup Raises Target Price to $60 From $52

THOMSON REUTERS
·
03 Jun

U.S. RESEARCH ROUNDUP-Biomea Fusion, GE Aerospace, P&G

Reuters
·
03 Jun

Kymera Therapeutics Inc : B. Riley Raises to Buy From Neutral; Raises Target Price to $60 From $38

THOMSON REUTERS
·
03 Jun

Kymera Therapeutics upgraded to Overweight from Equal Weight at Morgan Stanley

TIPRANKS
·
03 Jun

Kymera Therapeutics price target raised to $60 from $52 at Citi

TIPRANKS
·
03 Jun

BofA Securities Upgrades Kymera Therapeutics to Buy From Neutral, $51 Price Target; Shares Rise

MT Newswires Live
·
03 Jun